← Back to Clinical Trials
Recruiting NCT06679777

NCT06679777 Swedish CArdioPulmonary bioImage Study 2

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06679777
Status Recruiting
Phase
Sponsor Karolinska Institutet
Condition Cardiovascular Diseases
Study Type OBSERVATIONAL
Enrollment 30,154 participants
Start Date 2024-01-15
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30,154 participants in total. It began in 2024-01-15 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms. In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.

Eligibility Criteria

Inclusion Criteria: \- Participated in SCAPIS 1. Exclusion Criteria: * Individuals who have withdrawn their informed consent during or after SCAPIS 1.

Contact & Investigator

Central Contact

Tomas Jernberg, PhD

✉ tomas.jernberg@ki.se

📞 +46-70-1671474

Principal Investigator

Carl Johan Östgren, PhD

PRINCIPAL INVESTIGATOR

Linkoeping University

Frequently Asked Questions

Who can join the NCT06679777 clinical trial?

This trial is open to participants of all sexes, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06679777 currently recruiting?

Yes, NCT06679777 is actively recruiting participants. Contact the research team at tomas.jernberg@ki.se for enrollment information.

Where is the NCT06679777 trial being conducted?

This trial is being conducted at Gothenburg, Sweden, Linköping, Sweden, Lund, Sweden, Stockholm, Sweden and 2 additional locations.

Who is sponsoring the NCT06679777 clinical trial?

NCT06679777 is sponsored by Karolinska Institutet. The principal investigator is Carl Johan Östgren, PhD at Linkoeping University. The trial plans to enroll 30,154 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology